← Back

Entrada Therapeutics Inc

Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases. Its preclinical product includes ENTR-601-44; ENTR-601-45; and VX-670. The company was formerly known as CycloPorters, Inc., and changed its name to Entrada Therapeutics, Inc., in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Price · split & dividend adjusted
News & notes moving TRDA
TRDA▼

Entrada Therapeutics reports Q2 net loss of $42.8 million

Entrada Therapeutics reported a second-quarter net loss of $42.8 million, compared to a net loss of $43.1 million in the same quarter of 2025. Collaboration revenue fell to $0.9 million from $2 million a year earlier. As of June 30, 2026, the company held $223 million in cash, cash equivalents, and marketable securities, down from $295.7 million at the end of 2025.
TRDA ▼
Seeking Alpha·21dRead more ▾
Biotech & Genomic Medicine

Entrada Therapeutics reports second quarter 2026 financial results and pipeline progress

Entrada Therapeutics reported its second quarter 2026 financial results and highlighted upcoming clinical milestones. The company expects to report data from the Cohort 1 open-label period of the ELEVATE-44-201 study by year-end 2026, with Cohort 2 data expected in the first quarter of 2027. Data from Cohort 1 of the ELEVATE-45-201 study is anticipated in October 2026, while Cohort 2 dosing is ongoing at an increased dose of 10 milligrams per kilogram with data expected in the first half of 2027. Vertex is on track to report results from the Phase 1/2 trial of VX-670 in people with myotonic dystrophy type 1 in the second half of 2026. For the second quarter, Entrada posted a net loss of 42.8 million dollars, compared to 43.1 million dollars in the same period last year, and held cash, cash equivalents, and marketable securities of 223.0 million dollars as of June 30, 2026.
TRDA VRTX ▲
Biotech & Genomic Medicine
GlobeNewswire·21dRead more ▾
© 2026 MarketDXAsset